A second Covid vaccine developed by Oxford-AstraZeneca has been approved for use in the UK.
But how does it compare with the other vaccines?
The vast majority of people are still vulnerable to coronavirus. It’s only the current restrictions that are preventing more people from dying.
A vaccine would teach our bodies to fight the infection by stopping us from catching coronavirus, or at least making Covid less deadly.
Having a vaccine, alongside better treatments, is “the” exit strategy.
The Oxford vaccine was approved on 30 December following trials that it stops 70% of people developing Covid symptoms.
The data also shows a strong immune response in older people.
This may be one of the easiest vaccines to distribute, because it does not need to be stored at very cold temperatures.
It is made from a weakened version of a common cold virus from chimpanzees, that has been modified to not grow in humans.
The big breakthrough came when Pfizer-BioNTech published its first results in November.
The vaccine must be stored at a temperature of around -70C. It will be transported in a special box, packed in dry ice and installed with GPS trackers.
On 2 December, the UK became the first country in the world to approve the Pfizer/BioNTech coronavirus vaccine for widespread use.
Six days later 90-year-old Margaret Keenan became the first patient to receive the vaccine at University Hospital in Coventry. Since then, more than 600,000 people in the UK have been vaccinated.
The vaccine is a new type called an RNA, and uses a tiny fragment of the virus’s genetic code. This starts making part of the virus inside the body, which the immune system recognises as foreign and starts to attack.
An RNA vaccine has never been approved for use in humans before, although people have received them in clinical trials for other diseases.
Moderna uses the same approach as the Pfizer vaccine.
It is easier to store than Pfizer’s, because it stays stable at -20C for up to six months.
Other trial results are also expected in the coming weeks.
However, a trial in Brazil for a drug developed by the Chinese firm Sinovac was suspended after a “severe adverse incident” – believed to be a volunteer’s death.
Understanding which method produces the best results will be vital. Challenge trials, where people are deliberately infected, could help.
This depends on where Covid is spreading when the vaccine becomes available and in which groups each is most effective.
Older care home residents and staff top the UK’s preliminary priority list, followed by health workers like hospital staff, and the over-80s.
Age is, by far, Covid’s biggest risk factor.
It is thought that 60-70% of the global population must be immune to stop the virus spreading easily (herd immunity) – billions of people, even if the vaccine works perfectly.
People respond differently to immunisation.
History suggests any vaccine could be less successful in old people because an aged immune system does not respond as well, as happens with the annual flu jab. But data so far suggests this may not be a problem with some of Covid vaccines
Multiple doses may overcome any problems, as could giving it alongside a chemical (called an adjuvant) that boosts the immune system.
The British Broadcasting Corporation (#BBC) reports that a credible survey has revealed that a majority…
Vijay Prashad on why the US attack on Iran was illegal and why the attack…
The Minister for Education, Hon. Haruna Iddrisu, today announced a significant government commitment to bolster…
20th June, 2025- Accra, Ghana– “Professor Younge is not only bringing people to Ghana, but…
18/06/25 The Western Central Regional Police Command has arrested five suspects for armed robbery at…
Story by George Yawson Vineh The Africa University of Communications and Business (AUCB) in collaboration…